| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;110:3360-3366.)
© 2004 American Heart Association, Inc.
Vascular Medicine |
From the Center for Experimental Therapeutics and Department of Pharmacology (Y.H., Y.C., W.J., L.G., G.A.F., C.D.F.), University of Pennsylvania, Philadelphia, Pa; Merck Research Laboratories, Department of Cardiovascular Diseases, Rahway, NJ (I.S.); and the Departments of Physiology and Biochemistry, Queens University, Kingston, Ontario, Canada (C.D.F.).
Correspondence to Colin D. Funk, PhD, Department of Physiology, Queens University, Kingston, ON K7L 3N6 Canada. E-mail funkc{at}post.queensu.ca
Received May 14, 2004; revision received August 9, 2004; accepted August 23, 2004.
Background The proinflammatory and vascular actions of cysteinyl leukotrienes (CysLTs) are mediated by 2 receptors: cysteinyl leukotriene 1 receptor (CysLT1R) and cysteinyl leukotriene 2 receptor (CysLT2R). However, the distinct contribution of CysLT2R to the vascular actions of CysLTs has not been addressed.
Methods and Results We generated an endothelial cellspecific human CysLT2R (EC-hCysLT2R) transgenic (TG) mouse model using the Tie2 promoter/enhancer. Strong expression of hCysLT2R in TG lung and endothelial cells, detected by real-time polymerase chain reaction, markedly enhanced CysLT-stimulated intracellular calcium mobilization compared with endogenous expression in cells from nontransgenic mice. The permeability response to exogenous LTC4 and to endogenous CysLTs evoked by passive cutaneous anaphylaxis was augmented in TG mice. The rapid, systemic pressor response to intravenous LTC4 was also diminished in TG mice coincidentally with augmented production of nitric oxide.
Conclusions The development of EC-hCysLT2R mice has permitted detection of distinct vascular effects of CysLTs, which can be mediated via the CysLT2R in vivo.
Key Words: leukotrienes receptors endothelium edema blood pressure
Related Article:
Circulation 2004 110: 3289.
This article has been cited by other articles:
![]() |
M. P. W. Moos, J. D. Mewburn, F. W. K. Kan, S. Ishii, M. Abe, K. Sakimura, K. Noguchi, T. Shimizu, and C. D. Funk Cysteinyl leukotriene 2 receptor-mediated vascular permeability via transendothelial vesicle transport FASEB J, December 1, 2008; 22(12): 4352 - 4362. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Jiang, S. R. Hall, M. P.W. Moos, R. Y. Cao, S. Ishii, K. O. Ogunyankin, L. G. Melo, and C. D. Funk Endothelial Cysteinyl Leukotriene 2 Receptor Expression Mediates Myocardial Ischemia-Reperfusion Injury Am. J. Pathol., March 1, 2008; 172(3): 592 - 602. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Peters-Golden and W. R. Henderson Jr. Leukotrienes N. Engl. J. Med., November 1, 2007; 357(18): 1841 - 1854. [Full Text] [PDF] |
||||
![]() |
D. F. P. Leite, J. Echevarria-Lima, S. C. Ferreira, J. B. Calixto, and V. M. Rumjanek ABCC transporter inhibition reduces zymosan-induced peritonitis J. Leukoc. Biol., September 1, 2007; 82(3): 630 - 637. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Woszczek, L.-Y. Chen, S. Nagineni, S. Alsaaty, A. Harry, C. Logun, R. Pawliczak, and J. H. Shelhamer IFN-{gamma} Induces Cysteinyl Leukotriene Receptor 2 Expression and Enhances the Responsiveness of Human Endothelial Cells to Cysteinyl Leukotrienes J. Immunol., April 15, 2007; 178(8): 5262 - 5270. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Uzonyi, K. Lotzer, S. Jahn, C. Kramer, M. Hildner, E. Bretschneider, D. Radke, M. Beer, R. Vollandt, J. F. Evans, et al. Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells PNAS, April 18, 2006; 103(16): 6326 - 6331. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |